ArcticZymes Technologies ASA (FRA:B4V)

Market Cap	99.37M +65.8%
Revenue (ttm)	9.39M -0.7%
Net Income	614.39K +55.6%
EPS	0.01 +75.1%
Shares Out	n/a
PE Ratio	161.74
Forward PE	59.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	20
Open	1.860
Previous Close	1.865
Day's Range	1.860 - 1.885
52-Week Range	1.122 - 2.620
Beta	n/a
RSI	50.31
Earnings Date	Feb 12, 2026

About FRA:B4V

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 53
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: B4V

Financial Performance

In 2024, FRA:B4V's revenue was 108.11 million, a decrease of -9.65% compared to the previous year's 119.65 million. Earnings were 8.47 million, a decrease of -56.40%.

Financial numbers in NOK